- Organizations: BostonSight
Research
BostonSight's PROSE treatment linked to Mackie stage, VA gains in NK
Retrospective observational analysis supports the FDA-cleared scleral lens device as an effective tool in treating neurotrophic keratitis.Research
Pilot study evaluates scleral lens device and cyclosporine for DED drug delivery
Promising data on symptom and ocular surface tolerability supports using the customizable PROSE drug delivery system with cyclosporine 0.05%.Events
BostonSight introduces scleral lens fitting consultation program
“Beyond the Fit” features multiple programs designed to provide lens practitioners with tools to fit patients with a range of ocular conditions.Events